Carey said the take-home message is “if you have a patient who’s had MS and optic neuritis, and they call your office saying, ...
CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision. Fovlussea enters a European market where ranibizumab biosimilars have been commercially ...
The milestone moves what Oculis describes as the first genotype-guided registrational trial in DED a step closer to a readout ...
Prevent Blindness is observing its sixth annual Inflammatory Eye Disease (IED) Week from October 19 to 25, 2026, highlighting conjunctivitis and keratitis, thyroid eye disease (TED), and uveitis. 1 ...
Elizabeth A. Davis MD, FACS | Authors | The Eye Care Network delivers clinical news, expert interviews, and conference coverage across ophthalmology, retina, and optometry — uniting Ophthalmology ...
Patients who say their eyes feel dry, gritty, or burning are among the most common in ophthalmology, and treating them well ...
EURETINA President Nicole Eter, MD, picks the sessions busy clinicians should follow at the 26th EURETINA Congress in Vienna, from durability data to AI. She also explains why early referral is still ...
The 2 complement inhibitors approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA) secondary to ...
The FDA has approved Alcon’s apraclonidine ophthalmic solution 0.125% (Brytly), an over-the-counter eye drop for redness ...
SpyGlass Pharma has reported 4-year interim results from the first-in-human (FIH) trial of its Bimatoprost Drug Pad-IOL System (BIM-IOL System), extending what the company describes as the “longest ...
LUCIA, the second of 2 pivotal phase 3 trials in neovascular (wet) age-related macular degeneration (AMD), missed its primary ...
At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results